INBRX-109 Phase 2 Clinical Trial to Treat Unresectable or Metastatic Conventional Chondrosarcoma

Inhibrx has initiated a phase 2 clinical trial to treat unresectable or metastatic conventional chondrosarcoma. The poster was presented at the Connective Tissue Oncology Society (CTOS) in Vancouver, Canada from November 16-19.

The results of the phase 1 study indicated stable or reduced metastatic chondrosarcoma from the DR5 antagonist, the agent known as a death cell receptor. Side effects were few and tolerated and in many patients there was a noticeable reduction in pain.

The Phase 2 trial will include 230 patients with conventional chondrosarcoma treated at 51 sites around the globe including 30 in the United States, 3 in France, 2 in Germany, 1 in Ireland, 4 in the United Kingdom, 4 in Italy, 2 in the Netherlands, and 5 in Spain.

There is still room for 130 more CS patients. The most efficient way to enter the trial is working with your sarcoma specialist / oncologist. You can also e-mail Inhibrx to find out specific locations or ask specific questions at: clinincaltrials

For more information:

CTOS 2022- INBRX-109 Phase 2 Chondrosarcoma.pdf